Currently, infections caused by multidrug-resistant bacteria (MDR) such as carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) have become significant challenges in clinical treatment. According to the WHO, these infections are responsible for approximately 1.27 million deaths each year. Fosfomycin sodium, due to its unique mechanism of action, demonstrates irreplaceable clinical value in combination therapy, making it a key option for addressing the issue of drug resistance. The high-quality fosfomycin sodium produced by Jingjing Pharmaceutical Company enhances clinical efficacy through its stable quality. The core advantage of fosfomycin sodium lies in its mechanism of action: it targets the MurA enzyme in the early stages of bacterial cell wall synthesis, complementing the effects of β-lactams, tetracyclines, and oxazolidinones, thereby synergistically killing bacteria and reversing drug resistance. Studies have shown that the combination of fosfomycin and meropenem can significantly restore the sensitivity of CRE to meropenem, with MIC values decreasing by 4 to 8 times, indicating a clear effect on reversing resistance [1]. For carbapenem-resistant Klebsiella pneumoniae (CRKP), a triple therapy combining fosfomycin with tigecycline and polymyxin B can greatly improve the clinical cure rate in severe infections [2]. When used in combination with linezolid to treat MRSA, the in vitro synergistic effect exceeds 90%, and the bactericidal efficiency is significantly better than using the drugs alone [3]. Jingjing Pharmaceutical Company’s fosfomycin sodium provides reliable quality assurance for combination therapy, with high purity and low levels of impurities, ensuring a stable synergistic bactericidal effect. The strict aseptic control meets the needs of intravenous administration in severe infections. In clinical settings, this combination strategy is widely used in intensive care unit (ICU) infections, complex urinary tract infections, and postoperative infections, especially in children, the elderly, and patients with impaired liver or kidney function, where it offers significant safety benefits. In the face of the severe challenge of drug-resistant bacterial infections, the combination of fosfomycin sodium is a necessary clinical approach. With its high-quality fosfomycin sodium (CAS 26016-99-9), Jingjing Pharmaceutical Company contributes to solving the problem of drug resistance and provides a reliable guarantee for the research and development of clinical anti-infective therapies. References: [1] Wang Jin, Xiao Yonghong. In vitro synergistic effect of fosfomycin and meropenem against carbapenem-resistant Enterobacteriaceae bacteria [J]. Chinese Journal of Infectious Diseases, 2022, 40(8): 478-482. [2] Chinese Society of Critical Care Medicine. Guidelines for the Diagnosis and Treatment of Acquired Pneumonia/Ventilator-Associated Pneumonia in Adult Hospitals in China (2023 Edition) [J]. Chinese Journal of Critical Care Medicine, 2023, 9(2): 101-120. [3] Li Li, Zhang Jing, Wu Jufang. In vitro antibacterial activity of fosfomycin in combination with linezolid against methicillin-resistant Staphylococcus aureus [J]. Chinese Journal of Infectious Diseases and Chemotherapy, 2020, 20(3): 286-290.